Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ASH 2019
Pharma
J&J's Darzalex cuts death risk by 40% in new myeloma patients
New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.
Carly Helfand
Dec 9, 2019 4:30pm
Takeda details Ninlaro's miss in AL amyloidosis
Dec 9, 2019 3:41am
Novartis trumpets Adakveo hospitalization data
Dec 8, 2019 6:00pm
BeiGene, eyeing Imbruvica in CLL, touts more early Brukinsa data
Dec 8, 2019 4:45pm
Gilead touts 'astounding' Yescarta survival results at 3 years
Dec 8, 2019 12:26pm
AbbVie, Roche pad case for fixed-duration Venclexta use in CLL
Dec 8, 2019 11:16am
